Riopan (magaldrate) chewable tablets 800 mg. №20

Description

Riopan (magaldrate) chewable tablets 800 mg. №20

Composition

active substance: magaldrate;

1 chewable tablet contains 800 mg of anhydrous magaldrate;

excipients: sorbitol (E 420), polyethylene glycol 4000, maltol, aromatic caramel, aromatic cream, calcium behenate.

Medicinal form

Chewable tablets.

Main physicochemical properties: round, flat, white to light beige tablets with inclusions, chamfer on both sides and engraving “800” on one side.

Pharmacotherapeutic group

Antacids. Combinations and complex compounds of aluminum, calcium and magnesium.
Code ATX A02A D02.

Pharmacological properties

Riopan is an antacid with a layered lattice structure. The active substance of Riopan is magaldrate. It contains aluminum and magnesium hydroxide in one molecule.

Riopan reduces the amount of acid in the stomach and, depending on the dose and pH level, binds pepsin, bile acids and lysolecithin. This eliminates the aggressive action of gastric juice and forms a layer that protects its mucous membrane.

Acid binding is due to the binding of protons by sulfate and hydroxide ions of the middle layer of the lattice. During neutralization, the lattice structure collapses.
800 mg of anhydrous magaldrate neutralizes approximately 18-25 mg-eq of hydrochloric acid.

Riopan tablets corresponds in vitro to approximately 19 mg-eq of acid-neutralizing activity. Because the pH level is maintained in the range of 3 to 5 for 20-40 minutes, which is therapeutically optimal, the use of the drug does not cause acid rebound.
Magaldrate does not affect gastric motility.

Indication

Heartburn, sour belching, heaviness and fullness in the stomach.

Contraindication:

• Hypersensitivity to the active substance or to other components of the drug.
• Hypophosphatemia.
• Intrusion intolerance and sorbitol.
• Habitual constipation.
• Chronic diarrhea.
• Severe abdominal pain of unspecified origin.
• Alzheimer’s disease.

The drug can be used in patients with impaired renal function (creatinine clearance <30 ml / min) only with regular monitoring of plasma magnesium and aluminum levels. The level of aluminum in the blood plasma should not exceed 40 ng / ml.

Method of application and dosage

Adults: the recommended dose is 1 tablet of Riopan.
In case of minor complaints, the drug should be used 0.5–1 hour after a meal or immediately upon the appearance of significant complaints.

Riopan tablets should be swallowed or chewed thoroughly.
Do not exceed the maximum daily dose – 8 chewable tablets (6.4 g of magaldrate).
If the symptoms do not disappear after 2 weeks of treatment with the drug, you need to see a doctor for examination.
Elderly patients do not require dose adjustment.

Children

Currently, there are no data from systematic studies on the use and safety of the drug in children.

Overdose

No cases of overdose with Riopan tablets have been reported.
Symptoms of an overdose of aluminum hydroxide and magnesium hydroxide are manifested by rapid fatigue, flushing, exhaustion, muscle weakness and inappropriate behavior.
There may also be signs of metabolic alkalosis: mood swings or mental activity, numbness or muscle pain, nervousness and fatigue, slow breathing, unpleasant taste sensations.
Treatment of magnesium overdose: rehydration, forced diuresis. You can prescribe calcium gluconate intravenously. In case of renal failure, hemodialysis or peritoneal dialysis is required.

Side effects:

• From the digestive tract: diarrhea, constipation.
• In patients with renal insufficiency or long-term use of high doses of the drug may increase levels of aluminum and magnesium in the blood, which can lead to the accumulation of aluminum, mainly in nervous and bone tissues, and to a deficiency of phosphates.
• Disturbance of taste (feeling of taste of chalk); nausea; vomiting; aluminum and / or magnesium intoxication, most often in patients with renal insufficiency.
• Dementia, deterioration in Alzheimer’s disease.
• Osteomalacia, osteoporosis.
• Hypersensitivity reactions, including pruritus, urticaria, angioneurotic edema and anaphylactic reactions, bronchospasm.
• Reduction of phosphorus in the body is possible with the use of even the usual doses of the drug in patients whose diet is characterized by low phosphorus.
• Enhancement of resorption processes in bone tissue, hypercalciuria.

In patients with renal insufficiency, prolonged use of high doses of aluminum and magnesium salts may lead to the development of encephalopathy, microcytic anemia or worsen the course of osteomalacia induced by dialysis. Prolonged use or intake of high doses can cause phosphorus deficiency syndrome (loss of appetite, muscle weakness, weight loss).
Aluminum hydroxide can be dangerous for patients with porphyria who are on hemodialysis.